SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

SMS Pharmaceuticals informs about communication to shareholders

29 Aug 2024 Evaluate
In compliance with the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, SMS Pharmaceuticals has informed that the Company has sent reminder letter on 28th August, 2024 to shareholders holding shares in physical mode, requesting them to update/submit their PAN, KYC and Nomination details with the Registrar and Share Transfer Agents of the Company i.e., Aarthi Consultants. Copy of the reminder letter is enclosed. The above information and KYC Forms also be available on the website of the Company at www.smspharma.com

The above information is a part of company’s filings submitted to BSE.

SMS Pharmaceuticals Share Price

414.90 -5.70 (-1.36%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×